Current Report Filing (8-k)
January 10 2020 - 4:06PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event
Reported): January 10, 2020
Ekso Bionics Holdings, Inc.
(Exact Name of Registrant as specified in
its charter)
Nevada
|
|
001-37854
|
|
99-0367049
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
1414 Harbour Way South, Suite 1201
Richmond, California 94804
(Address of principal executive offices,
including zip code)
(510) 984-1761
(Registrant’s telephone number, including
area code)
Not Applicable
(Registrant’s former name or former
address, if changed since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, $0.001 par value per share
|
|
EKSO
|
|
Nasdaq Capital Market
|
|
|
|
|
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
|
¨
|
|
|
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
Item 2.02
|
Results of Operations and Financial
Condition
|
On January 10, 2020,
Ekso Bionics Holdings, Inc. (the “Company”) issued a press release (the “Press Release”) announcing certain
preliminary financial results for the quarter and year ended December 31, 2019.
The full text of the
Press Release announcing such results is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in Item
2.02 of this Current Report on Form 8-K, including the information contained in Exhibit 99.1, is being furnished and shall not
be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or incorporated
by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation
language in such filing.
The Press Release also
includes information including:
|
·
|
Revenue for the fourth quarter of 2019
was an estimated $3.7 million, reflecting year-over-year growth of 12.1%, compared to total revenue of $3.3 million in the fourth
quarter of 2018, including approximately $3.2 million in medical revenue and approximately $0.5 million on shipments of industrial
products
|
|
·
|
Total revenue for fiscal year 2019 is
estimated to be approximately $13.9 million, compared to $11.3 million in 2018. This reflects estimated year-over-year growth of
23.0%
|
|
·
|
Cash on hand as of December 31, 2019 is
estimated to be approximately $10.9 million, compared to cash on hand as of December 31, 2018 of $7.7 million
|
The estimated, projected
or anticipated financial results, financial condition or other financial information discussed in this Current Report on Form
8-K are based on management’s preliminary unaudited analysis of financial results for the period and year ended December
31, 2019. As of the date of this report, the Company has not completed its financial statement reporting process for the period
ended December 31, 2019, and the Company’s independent registered accounting firm has not audited the preliminary financial
data discussed in this Current Report on Form 8-K. During the course of the Company’s quarter-end closing procedures and
review process, including the finalization of its financial statements for and as of the period and year ended December 31, 2019,
the Company may identify items that would require it to make adjustments, which may be material to the information presented above.
As a result, the estimates above constitute forward-looking information. Such forward-looking statements are not meant to predict
or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's
current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to risks and uncertainties
that may cause the actual results and timing of certain events and circumstances to be materially different from those described
by the forward-looking statements. Such resulting differences may include material adjustments to the information provided above.
The Company does not undertake to update these forward-looking statements.
Item 9.01
|
Financial Statements and Exhibits
|
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
|
EKSO BIONICS HOLDINGS, INC.
|
|
|
|
|
|
By:
|
/s/
|
John F. Glenn
|
|
Name:
|
John F. Glenn
|
|
Title:
|
Chief Financial Officer
|
Dated: January 10, 2020
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Apr 2023 to Apr 2024